Want to see AU:ACR full AI Analyst Report?
ACR Stock Chart & Stats
AU$0.01
>-AU$0.01(-8.33%)
At close: 4:00 PM EDT
AU$0.01
>-AU$0.01(-8.33%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume169.96K
Average Volume (3M)715.88K
Market Cap
AU$6.67M
Enterprise ValueAU$5.85
Total Cash (Recent Filing)AU$1.71M
Total Debt (Recent Filing)AU$2.52M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield9.09%
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding606,344,500
10 Day Avg. Volume100,243
30 Day Avg. Volume715,875
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.46
Price to Sales (P/S)1.09
P/FCF Ratio4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)AU$14.20M
Bulls Say, Bears Say
Bulls Say
2026 Revenue ReboundThe sharp 2026 revenue recovery indicates renewed commercial activity after prior declines and provides a stronger base for future operating leverage. If revenue remains elevated, it could support improved cost absorption, reinvestment, and progress toward sustainable profitability over the next several quarters.
Positive Operating And Free Cash FlowPositive operating and free cash flow is an important improvement for a company that has recorded recurring losses. It demonstrates that recent business activity generated cash internally, potentially reducing near-term reliance on external funding and supporting greater financial flexibility.
Narrowing Net LossA materially narrower net loss suggests that the revenue recovery is beginning to improve earnings performance, even though profitability has not yet been achieved. Continued progress would reduce cash demands, strengthen the path toward breakeven, and improve the durability of the business model.
Bears Say
Persistent UnprofitabilityRecurring net, EBIT, and EBITDA losses show that the current operating model has not yet produced sustainable profitability. Continued losses can consume financial resources, limit self-funded investment, and make future performance dependent on maintaining revenue gains and controlling costs.
Higher Leverage And Compressed EquityA sharply compressed equity base and higher debt-to-equity ratio leave less balance-sheet protection for creditors and shareholders. This weaker cushion is particularly important for a biotechnology company with recurring losses, because it reduces financial flexibility if operating performance deteriorates.
Volatile Revenue And Cash GenerationLarge swings in revenue and free cash flow make it difficult to establish a dependable operating trajectory. Although 2026 cash generation improved, prior negative periods show that cash burn can re-emerge if revenue normalizes or expenses rise, increasing funding pressure.
Acrux News
ACR FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is AU$6.67M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Mar 02, 2027 which is in 176 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Aug 21, 2026. The company reported -AU$0.002 earnings per share for the quarter.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited pays a Annually dividend of AU$0.06 which represents an annual dividend yield of 9.09%. See more information on Acrux Limited dividends here
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 606,344,500 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of -AU$0.002 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in AU:ACR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrux Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
AU:ACR Sentiment 67%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth AU$149.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.39%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Acrux Limited
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets. The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels. Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.
Technical Analysis
Clinuvel Pharmaceuticals
―
Starpharma Holdings Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―